Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,070 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study.
Oita M, Miyoshi H, Ono K, Nakamura A, Cho KY, Nomoto H, Yamamoto K, Omori K, Manda N, Kurihara Y, Aoki S, Atsumi T. Oita M, et al. Among authors: omori k. Endocr J. 2018 Feb 26;65(2):141-150. doi: 10.1507/endocrj.EJ17-0303. Epub 2017 Oct 31. Endocr J. 2018. PMID: 29093280 Free article. Clinical Trial.
Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.
Cho KY, Nakamura A, Omori K, Takase T, Miya A, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Cho KY, et al. Among authors: omori k. Diabetes Obes Metab. 2019 Mar;21(3):710-714. doi: 10.1111/dom.13557. Epub 2018 Nov 8. Diabetes Obes Metab. 2019. PMID: 30311367 Free PMC article. Clinical Trial.
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Cho KY, et al. Among authors: omori k. Diabetes Obes Metab. 2020 Mar;22(3):458-462. doi: 10.1111/dom.13879. Epub 2019 Oct 13. Diabetes Obes Metab. 2020. PMID: 31486230 Free PMC article. Clinical Trial.
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
Kameda R, Nomoto H, Cho KY, Kawata S, Omori K, Takeuchi J, Nagai S, Kurihara Y, Aoki S, Nakamura A, Atsumi T, Miyoshi H. Kameda R, et al. Among authors: omori k. BMJ Open. 2020 Feb 6;10(2):e034883. doi: 10.1136/bmjopen-2019-034883. BMJ Open. 2020. PMID: 32034028 Free PMC article.
Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
Cho KY, Nakamura A, Omori K, Takase T, Miya A, Yamamoto K, Nomoto H, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Cho KY, et al. Among authors: omori k. J Diabetes Investig. 2021 Jul;12(7):1272-1277. doi: 10.1111/jdi.13457. Epub 2020 Dec 2. J Diabetes Investig. 2021. PMID: 33131199 Free PMC article. Clinical Trial.
1,070 results